3
Views
0
CrossRef citations to date
0
Altmetric
Original Paper

Anemia in intensive care units

, , , &
Pages 49-55 | Published online: 30 Dec 2011

References

  • Vincent JL, Baron JF, Reinhart K, et al. Anemia and blood transfusion in critically ill patients. JAMA 2002; 288: 1525— 6.
  • Corwin HL, Parsonnet K, Gettinger A. RBC transfusion in the ICU. Is there a reason? Chest 1995; 108: 767— 71.
  • Ashen NC, Muller C, Serke S, Frei U, Eckardt K. Important role of nondiagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care patients. Crit Care Med 1999; 27: 2630— 9.
  • Smoller BR, Kruskall MS. Phlebotomy for diagnostic laboratory tests in adults: pattern of use and effect on transfusion requirements. N Engl I Med 1986; 314: 1233–5.
  • Katzung BG. Basic and Clinical Pharmacology. CT; Appleton & Lange, 1995: 503–4.
  • Hobisch-Hagen P, Wiedermann F, Mayr A, et al. Blunted erythropoietic response to anemia in multiply traumatized patients. Crit Care Med 2001; 29: 743–7.
  • Weiss G, Wider B, Zoller H, et al. Immune response and iron metabolism. Br I Anaesth 1998; 81 (Suppl. 1): 6–9.
  • Jelkmann W, Pagel H, Wolff M, et al. Monokines inhibiting erythropoietin production in human hepatoma cultures and and isolated perfused rat kidneys. Life Sci 1992; 50: 301–8.
  • Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. I Interferon Cytokine Res 1998; 18: 555–9.
  • Littenberg B, Corwin HC, Gettinger A, et al. A practice guideline and decision aide for blood transfusion. Immunohematology 1995; 11: 88–94.
  • Hebert PC, Wells G, Marshall J, et al. Transfusion requirements in critical care: A pilot study. JAMA 1995; 274: 944.
  • Possible transfusion-associated acquired immune deficiency syndrome (AIDS) California. MMWR Morb Mortal Wkly Rep 1982; 31: 652–4.
  • Schreiber GB, Busch MP, Kleinman SH, Korelitz II. The risk of transfusion-transmitted viral infections. N Engl J Med 1996; 334: 1685–90.
  • Dodd RY. Adverse consequences of blood transfusion: quantitative risk estimates. In: Nance ST (ed.). Blood Supply: Risks Perceptions, and Prospects for the Future. Bethesda, MD; American Association of Blood Banks, 1994: 1–24.
  • Ness PM, Shirley RS, Thoman SK, Buck SA. The differentiation of delayed serologic and delayed hemolytic transfusion reactions: incidence, long-term serologic findings, and clinical significance. Transfusion 1990; 30: 688–93.
  • Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 1990; 30: 583–90.
  • Linden JV, Paul B, Dressler KP. A report of 104 transfusion errors in New York State. Transfusion 1992; 32: 601–6.
  • Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985; 25: 573–7.
  • Silliman CC, Paterson AJ, Dickey WO, et al. The association of biologically active lipids with the development of transfusion-related acute lung injury: a retrospective study. Transfusion 1997; 37: 719–26.
  • Marik PE, Sibbald WJ. Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA 1993; 269: 3024–9.
  • Eichelbronner O, Sielenkamper A, Cepinskas G, et al. Endotoxin promotes adhesion of human erythrocytes to human vascular endothelial cells under conditions of flow. Crit Care Med 2000; 28: 1865–70.
  • Fitzgerald RD, Martin CM, Dietz GE, et al. Transfusing red blood cells stored in citrate phosphate dextrose adenine-1 for 28 days fails to improve tissue oxygenation in rats. Crit Care Med 1997; 25: 723–4.
  • Walsh TS, McArdle F, McLellan SA, et al. Does the storage of transfused red cells influence regional or global indexes of tissue oxygenation in anemic critically ill patients? Crit Care Med 2004; 32: 364–71.
  • Purdy FR, Tweeddale MG, Merrick PM. Association of mortality with age of blood transfused in septic ICU patients. Can I Anaesth 1997; 44: 1256–61.
  • Blumberg N, Triulzi DJ, Heal JM. Transfusion-in-duced immunomodulation and its clinical consequences. Transfus Med Rev 1990; 4 (Suppl. 1): 24–35.
  • Ikuta S, Mild C, Hatada T, et al. Allogenic blood transfusion is an independent risk factor for infective complications after less invasive gastrointestinal surgery. Am J Surg 2003; 185: 188–93.
  • Ottino G, De Paulis R, Pansini S, et al. Major sternal wound infection after open-heart surgery: a multi-variate analysis of risk factors in 2,579 consecutive operative procedures. Ann Thorac Surg 1987; 44: 173–9.
  • Fransen E, Maessen J, Denener M, Senden N, Buurman W. Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery. Chest 1999; 116: 1233–9.
  • Taylor RW, Manganaro L, O'Brien J, Trottier SJ, Parkar N, Veremakis C. Impact of allogenic packed red blood cell transfusion on nosocomial infection rates in the critically ill patient. Crit Care Med 2002; 30: 2249–54.
  • Leal-Novel SR, Rincon-Ferrari MD, Garcia-Curiel A, et al. Transfusion of blood components and postoperative infection in patients undergoing cardiac surgery. Chest 2001; 119: 1461–8.
  • Weiskopf RB, Viele MK, Feiner J, Kelley S, Lieberman J, Noorani M, leung JM, Fisher DM, Murray WR, Toy P, Moore MA. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA 1998; 279: 217–21.
  • Fontana JL, Welborn L, Mongan PD, Sturm P, Martin G, Bunger R. Oxygen consumption and cardiovascular function in children during profound intraoperative normovolemic hemodilution. Anesth Analg 1995; 80: 219–25.
  • Spahn DR, Zollinger A, Schlumpf RB, et al. Hemodilution tolerance in elderly patients without known cardiac disease. Anesth Analg 1996; 82: 681–6.
  • Carson JL, Duff A, Berlin JA, et al. Perioperative blood transfusion and postoperative mortality. JAMA 1998; 278: 199–205.
  • Carson JL, Noveck H, Berlin JA, Gould SA. Mortality and morbidity in patients with low postoperative Hb levels who decline blood transfusion. Transfusion 2002; 42: 812–8.
  • Adams RC, Lundy JS. Anesthesia in cases of poor surgical risk: some suggestions for decreasing the risk. Surg Gynecol Obstet 1942; 74: 1011.
  • Carmel R, Shulman IA. Blood transfusion in medically treatable chronic anemia: pernicious anemia as a model for transfusion overuse. Arch Pathol Lab Med 1989; 113: 995–7.
  • Hebert PC, Wells G, Martin C, et al. A Canadian survey of transfusion practices in critically ill patients. Transfusion Requirements in Critical Care Investigators and the Canadian Critical Care Trials Group. Crit Care Med 1998; 26: 482–7.
  • Hebert PC, Wells G, Blajchman MA, et al. A multi-center, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl I Med 1999; 340: 409–17.
  • Spahn DR, Schmid ER, Seifert B, Pasch T. Hemodilution tolerance in patients with coronary artery disease who are receiving chronic beta-adrenergic blocker therapy. Anesth Analg 1996; 82: 687–94.
  • Spiess BD, Ley C, Body SC, et al. Hematocrit value on intensive care unit entry influences the frequency of Q-wave myocardial infarction after coronary artery bypass grafting. The Institutions of the Multicenter Study of Perioperative Ischemia (McSPI) Research Group. I Thorac Cardiovasc Surg 1998; 116: 460–7.
  • Wu WC, Rathore SS, Radford MJ, et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl I Med 2001; 345: 1230–6.
  • Jacobson LO, Goldwasser E, Fried W, Plzak L. Role of the kidney in erythropoiesis. Nature 1957; 179: 633–4.
  • Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. I Biol Chem 1977; 252: 5558–64.
  • Jacobs K, Shoemaker C, Rudersdorf R, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985; 313: 806–10.
  • Lin FK, Suggs S, Lin CH, etal. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985; 82: 7580–4.
  • Inoue N, Takeuchi M, Ohashi H, Suzuki T. The production of recombinant human erythropoietin. Biotechnol Annu Rev 1995; 1: 297–313.
  • Storring PL, Tiplady RJ, Gaines DR, et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br I Haematol 1998; 100: 79–89.
  • Halstenson CE, Macres M, Katz SA, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991; 50: 702–12.
  • Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 1992; 72: 449–89.
  • Horina JH, Petritsch W, Schmid CR, et al. Treatment of anemia in inflammatory bowel disease with recombinant human erythropoietin: results in three patients. Gastroenterology 1993; 104: 1828–31.
  • Means-RT, Jr, Olsen NJ, Krantz SB, et al. Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin: clinical and in vitro studies. Arthritis Rheum 1989; 32: 638–42.
  • Fischl M, Galpin JE, Levine JD, et al. Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin: clinical and in vitro studies. N Engl I Med 1990; 322: 1488–93.
  • Henry DH. Clinical application of recombinant erythropoietin in anemic cancer patients. Hematol Oncol Clin North Am 1994; 8: 961–73.
  • Spence RK. Surgical red blood cell transfusion practice policies. Blood Management Practice Guidelines Conference. Am I Surg 1995; 170 (Suppl. 6A): 3S–15.
  • Maier RF, Obladen M, Muller-Hansen I, et al. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. I Pediatr 2002; 141: 8–15.
  • Corwin HL, Gettinger A, Rodriguez RM, et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med 1999; 27: 2346–50.
  • Corwin HL, Gettinger A, Pearl RG, et al. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 2002; 288: 2827–35.
  • Lavediere C, Gauvin F, Hebert PC, et al. Survey on transfusion practices of pediatric intensivists. Pediatr Crit Care Med 2002; 3: 335–40.
  • Allyson M, Goodman, Murray M, et al. Pediatric red blood cell transfusions increase resource use. I Pediatr 2003; 142: 123–7.
  • Ohls RK, Ehrenkranz RA, Wright LL, Lemons JA, Korones SB, Stoll BJ. Effects of early erythropoitin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics 2001; 108: 934–42.
  • Jacobs BR, Lyons K, Brilli RJ. Erythropoietin therapy in children with bronchilotis and anemia. Pediatr Crit Care Med 2003; 4: 44–8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.